Soluble urinary CD14 after intravesical bacille Calmette‐Guérin immunotherapy for carcinoma in situ

Abstract

Objective To characterize the production of the monoalthough in most patients there was a minor band of reactivity at 54 kDa. A panel of human bladder cancer cyte activation marker, soluble CD14 (sCD14), after bacille Calmette-Guérin (BCG) immunotherapy for cell lines did not react with the anti-CD14 monoclonal antibodies 3C10, 5C5 and BA8, and the antibodies superficial bladder cancer. Patients and methods Nineteen patients with carcinoma also failed to react with malignant epithelial cells in frozen sections of untreated bladder tumour. in situ were treated with a standard regimen of intravesical BCG. Urine samples were collected after each Furthermore, sCD14 was not secreted by cultured bladder tumour cells. The source of urinary sCD14 is instillation and analysed; the levels of soluble CD14 were determined by an enzyme-linked immunosorbent likely to be the resident and infiltrating macrophages in the bladder wall. Freshly isolated peripheral blood assay, the molecular weight confirmed by Western blotting and the possible cell source investigated using monocytes secreted sCD14 in response to BCG in a manner analogous to stimulation with bacterial lipoimmunohistochemistry.Results The mean levels of sCD14 were higher in polysaccharide. Conclusion A soluble form of CD14 is secreted into the patients with persistent carcinoma (designated as failures) than in those who had successful complete urine of patients who receive intravesical BCG. The measurement of soluble urinary CD14 could be of responses (responders) to BCG immunotherapy. The diÂerences were statistically significant, with P= prognostic significance for the response to immunotherapy. 0.034 at instillation 4 and P=0.027 at instillation 5 for the total mass of sCD14, and P=0.049 at instilKeywords Bacille Calmette-Guérin, BCG, lipopolysaccharide, bladder cancer, CD14 lation 4 for the concentration of sCD14. The predominant type of sCD14 in urine was the 48 kDa form, bladder wall is infiltrated by many neutrophils, lympho-

Endogenous Neutralizing Antibodies Against Platelet-Derived Growth Factor-AA Inhibit Atherogenesis in the Cholesterol-Fed Rabbit

“…The adjuvant administered to both experimental and control groups, however, contained Mycobacterium bovis, which is well known to produce both strong humoral and cellular immune responses. [21][22][23][24][25] Indeed, we found equivalent levels of anti-Mycobacterium antibodies in the plasma of animals from all groups. We consider it unlikely that the immune responses to PDGF-AA, platelet proteins, and saline (other than the specific activity of the antibodies) differentially effected atherogenesis in the 3 groups against the background of the immune response to Mycobacterium bovis.…”

Intravesical Treatment of Bladder Cancer; Current Problems and Needs

“…Several investigators have studied cytokine secretion in response to BCG instillation. Jackson et al [18] showed that the urine levels of soluble CD14 is significantly higher in patients responding to BCG therapy as compared with nonresponders. In a small study on 20 patients receiving BCG treatment for superficial bladder cancer, Thalmann et al [16] observed that only 1 of 10 patients with urinary IL-8 concentrations Ͼ4 g/l 6 h after BCG instillation had a tumor recurrence, while all patients with urinary soluble CD14 concentrations Ͻ4 g/l subsequently developed a tumor recurrence.…”

“…Increases of interleukin (IL)1ß, IL-2 [1214], IL-8 [15,16], interferon gamma (IFN-␥) [17], tumor necrosis factor alpha (TNF-␣), and soluble CD14 [18], a monocyte activation marker, have been reported. The secretion of these factors clearly demonstrates the presence of an immune reaction, and, furthermore, there is some evidence that the intensity of this secretion can even be linked with the response to BCG treatment.…”